A biotech startup focused on eye diseases has secured $330 million in funding, gearing up for late-stage testing of its treatments. This significant investment marks a pivotal moment in ophthalmology care and underlines the growing interest in targeted therapies for chronic conditions.

Alvotech has entered key supply and commercialization agreements with Sandoz to expand biosimilar treatments in Canada and across Australia and New Zealand. The deal covers multiple therapeutic areas—ophthalmology, immunology, and gastroenterology—and positions both companies to broaden patient access through shared responsibilities in development, manufacturing, and distribution.

Singapore Eye Research Institute has claimed the top position among non-academic institutes worldwide, according to rankings by ScholarGPS. It also ranks second among all institutes in the field of ophthalmology, highlighting its global impact on eye research.

Oculis will unveil its second-quarter 2025 results before the opening bell on Aug. 26. Wall Street is bracing for a 53-cent loss on scant revenue of $140,000, putting fresh pressure on the ophthalmology firm whose shares opened at $18.06 this week.